Management of Gynecological Cancers During Pregnancy

Current Oncology Reports

Volumn 16, Issue 12, 2014, Pages

  Han, Sileny N ^a   Verheecke, Magali ^a   Vandenbroucke, Tineke ^a   Mhallem Gziri, Mina ^b   Van Calsteren, Kristel ^a   Amant, Frédéric ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Cancer; Cervical; Chemotherapy; Gynecologic; Ovarian; Pregnancy; Surgery; Vulvar

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; ERYTHROMYCIN DERIVATIVE; MORPHINE; PARACETAMOL; PENICILLIN DERIVATIVE; TRAMADOL; TUMOR MARKER; UTERUS SPASMOLYTIC AGENT;

ANTIBIOTIC PROPHYLAXIS; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER THERAPY; ECHOGRAPHY; FEMALE; GYNECOLOGIC CANCER; HUMAN; MATERNAL DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVARY CANCER; PATIENT SAFETY; PLACENTAL TRANSFER; POSTOPERATIVE ANALGESIA; REVIEW; SENTINEL LYMPH NODE; THROMBOSIS PREVENTION; UTERINE CERVIX CANCER; VULVA CANCER; EVIDENCE BASED MEDICINE; GENITAL NEOPLASMS, FEMALE; GYNECOLOGIC SURGERY; PATHOLOGY; PRACTICE GUIDELINE; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; PREGNANCY OUTCOME; PRENATAL DIAGNOSIS; PRENATAL EXPOSURE; PROCEDURES; PROGNOSIS; RISK FACTOR; SENTINEL LYMPH NODE BIOPSY;

ANTINEOPLASTIC AGENTS; EVIDENCE-BASED MEDICINE; FEMALE; GENITAL NEOPLASMS, FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; PREGNANCY OUTCOME; PRENATAL DIAGNOSIS; PRENATAL EXPOSURE DELAYED EFFECTS; PROGNOSIS; RISK FACTORS; SENTINEL LYMPH NODE BIOPSY;

EID: 84911936873     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-014-0415-z     Document Type: Review

References (53)

1. Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol. 2013;121:829–46.
2. Aggarwal P., Kehoe S. Ovarian tumours in pregnancy: a literature review. Eur J Obstet Gynecol Reprod Biol. 2010.
3. Leiserowitz GS, Xing G, Cress R, Brahmbhatt B, Dalrymple JL, Smith LH. Adnexal masses in pregnancy: how often are they malignant? Gynecol Oncol. 2006;101:315–21.
4. Turkcuoglu I, Meydanli MM, Engin-Ustun Y, Ustun Y, Kafkasli A. Evaluation of histopathological features and pregnancy outcomes of pregnancy associated adnexal masses. J Obstet Gynaecol. 2009;29:107–9.
5. Giuntoli RL, Vang RS, Bristow RE. Evaluation and management of adnexal masses during pregnancy. Clin Obstet Gynecol. 2006;49:492–505.
6. Morice P, Uzan C, Gouy S, Verschraegen C, Haie-Meder C. Gynaecological cancers in pregnancy. Lancet. 2012;379:558–69. Comprehensive review on treatment of gynaecological cancers in pregnancy. This paper is part of a Series of three papers about malignancies in pregnancy.
7. Amant F., Halaska M.J., Fumagalli M., Dahl S.K., Lok C., Van C.K. et al. Gynecologic Cancers in Pregnancy: Guidelines of a Second International Consensus Meeting. Int J Gynecol Cancer. 2014. Most recent consensus guidelines composed by a multidisciplinary team of physicians specialized in treatment of cancer in pregnancy.
8. Nguyen C, Montz FJ, Bristow RE. Management of stage I cervical cancer in pregnancy. Obstet Gynecol Surv. 2000;55:633–43.
9. Han SN, Lotgerink A, Gziri MM, Van CK, Hanssens M, Amant F. Physiologic variations of serum tumor markers in gynecological malignancies during pregnancy: a systematic review. BMC Med. 2012;10:86.
10. Moore RG, Miller MC, Eklund EE, Lu KH, Bast Jr RC, Lambert-Messerlian G. Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. Am J Obstet Gynecol. 2012;206:349.e1–7.
11. Kanal E, Barkovich AJ, Bell C, Borgstede JP, Bradley Jr WG, Froelich JW, et al. ACR guidance document for safe MR practices: 2007. AJR Am J Roentgenol. 2007;188:1447–74.
12. Balleyguier C, Fournet C, Ben HW, Zareski E, Morice P, Haie-Meder C, et al. Management of cervical cancer detected during pregnancy: role of magnetic resonance imaging. Clin Imaging. 2013;37:70–6.
13. Nijman T, Schutter E, Amant F. Sentinel node procedure in vulvar carcinoma during pregnancy: a case report. Gynecol Oncol Rep. 2012;2:63–4.
14. Van Calsteren K, Heyns L, De Smet F, Van Eycken L, Gziri MM, Van Gemert W, et al. Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. J Clin Oncol. 2010;28:683–9.
15. Augustin G, Majerovic M. Non-obstetrical acute abdomen during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2007;131:4–12.
16. Moreno-Sanz C, Pascual-Pedreno A, Picazo-Yeste JS, Seoane-Gonzalez JB. Laparoscopic appendectomy during pregnancy: between personal experiences and scientific evidence. J Am Coll Surg. 2007;205:37–42.
17. Grimm D., Woelber L., Trillsch F., Keller V., Mahner S. Clinical management of epithelial ovarian cancer during pregnancy. Eur J Cancer. 2014.
18. Wilasrusmee C, Sukrat B, McEvoy M, Attia J, Thakkinstian A. Systematic review and meta-analysis of safety of laparoscopic versus open appendicectomy for suspected appendicitis in pregnancy. Br J Surg. 2012;99:1470–8.
19. Schmeler KM, Frumovitz M, Ramirez PT. Conservative management of early stage cervical cancer: is there a role for less radical surgery? Gynecol Oncol. 2011;120:321–5.
20. Benedet JL, Bender H, Jones III H, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet. 2000;70:209–62.
21. Matsuo K., Whitman S.A., Blake E.A., Conturie C.L., Ciccone M.A., Jung C.E. et al. Feto-maternal outcome of pregnancy complicated by vulvar cancer: a systematic review of literature. Eur J Obstet Gynecol Reprod Biol. 2014. Recent systematic review on vulvar cancer during pregnancy.
22. Kuczkowski KM. Advances in obstetric anesthesia: anesthesia for fetal intrapartum operations on placental support. J Anesth. 2007;21:243–51.
23. S.C. Hughes, G. Levinson, M.A. Rosen. Shnider and Levinson’s Anesthesia for Obstetrics. 2002.
24. Evans SR, Sarani B, Bhanot P, Feldman E. Surgery in pregnancy. Curr Probl Surg. 2012;49:333–88.
25. Yumi H. Guidelines for diagnosis, treatment, and use of laparoscopy for surgical problems during pregnancy: this statement was reviewed and approved by the Board of Governors of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), September 2007. It was prepared by the SAGES Guidelines Committee. Surg Endosc. 2008;22:849–61.
26. Anderka M, Mitchell AA, Louik C, Werler MM, Hernandez-Diaz S, Rasmussen SA. Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects. Birth Defects Res A Clin Mol Teratol. 2012;94:22–30.
27. Pasternak B, Svanstrom H, Hviid A. Ondansetron in pregnancy and risk of adverse fetal outcomes. N Engl J Med. 2013;368:814–23. Annotation: safety of ondasetron for the fetus is studied in the largest cohort to date.
28. Hernandez RK, Werler MM, Romitti P, Sun L, Anderka M. Nonsteroidal antiinflammatory drug use among women and the risk of birth defects. Am J Obstet Gynecol. 2012;206:228.
29. Koren G, Florescu A, Costei AM, Boskovic R, Moretti ME. Nonsteroidal antiinflammatory drugs during third trimester and the risk of premature closure of the ductus arteriosus: a meta-analysis. Ann Pharmacother. 2006;40:824–9.
30. van Hasselt J.G., Van Calsteren K., Heyns L., Han S.N., Mhallem G.M., Schellens J.H. et al. Optimizing anti-cancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel. Ann Oncol. 2014. Pharmacokinetics of chemotherapy during pregnancy (doxorubicin, epirubicin, docetaxel and paclitaxel), showed a decrease in drug exposure during pregnancy when compared to the nonpregnant patient.
31. Loibl S, Han SN, von Minckwitz G, Bontenbal M, Ring A, Giermek J, et al. Treatment of breast cancer during pregnancy: an observational study. Lancet Oncol. 2012;13:887–96.
32. Amant F, von Minckwitz G, Han SN, Bontenbal M, Ring AE, Giermek J, et al. Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. J Clin Oncol. 2013;31:2532–9.
33. Ni Z, Mao Q. ATP-binding cassette efflux transporters in human placenta. Curr Pharm Biotechnol. 2011;12:674–85.
34. Ceckova-Novotna M, Pavek P, Staud F. P-glycoprotein in the placenta: expression, localization, regulation and function. Reprod Toxicol. 2006;22:400–10.
35. Van Calsteren K, Verbesselt R, Devlieger R, De Catte L, Chai DC, Van Bree R, et al. Transplacental transfer of paclitaxel, docetaxel, carboplatin, and Trastuzumab in a baboon model. Int J Gynecol Cancer. 2010;20:1456–64.
36. Van Calsteren K, Verbesselt R, Ottevanger N, Halaska M, Heyns L, Van Bree R, et al. Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical study. Acta Obstet Gynecol Scand. 2010;89:1338–45.
37. Aviles A, Niz J. Long-term follow-up of children born to mothers with acute leukemia during pregnancy. Med Pediatr Oncol. 1988;16:3–6.
38. Amant F, Van Calsteren K, Halaska MJ, Gziri MM, Hui W, Lagae L, et al. Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study. Lancet Oncol. 2012;13:256–64.
39. Cardonick E, Gilmandyar D, Somer RA. Maternal and neonatal outcomes of dose-dense chemotherapy for breast cancer in pregnancy. Obstet Gynecol. 2012;120:1267–72.
40. Abdel-Hady E, Hemida RA, Gamal A, El-Zafarany M, Toson E, El-Bayoumi MA. Cancer during pregnancy: perinatal outcome after in utero exposure to chemotherapy. Arch Gynecol Obstet. 2012;286:283–6.
41. Cardonick E, Bhat A, Gilmandyar D, Somer R. Maternal and fetal outcomes of taxane chemotherapy in breast and ovarian cancer during pregnancy: case series and review of the literature. Ann Oncol. 2012;23:3016–23.
42. Aviles A, Neri N. Hematological malignancies and pregnancy: a final report of 84 children who received chemotherapy in utero. Clin Lymphoma. 2001;2:173–7.
43. Hahn KM, Johnson PH, Gordon N, Kuerer H, Middleton L, Ramirez M, et al. Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer. 2006;107:1219–26.
44. Aviles A, Neri N, Nambo MJ. Long-term evaluation of cardiac function in children who received anthracyclines during pregnancy. Ann Oncol. 2006;17:286–8.
45. Gziri MM, Debieve F, De Catte L, Mertens L, Barrea C, Van Calsteren K, et al. Chemotherapy during pregnancy: effect of anthracyclines on fetal and maternal cardiac function. Acta Obstet Gynecol Scand. 2012;91:1465–8.
46. Gziri MM, Hui W, Amant F, Van CK, Ottevanger N, Kapusta L, et al. Myocardial function in children after fetal chemotherapy exposure. A tissue Doppler and myocardial deformation imaging study. Eur J Pediatr. 2013;172:163–70.
47. Zagouri F, Sergentanis TN, Chrysikos D, Bartsch R. Platinum derivatives during pregnancy in cervical cancer: a systematic review and meta-analysis. Obstet Gynecol. 2013;121:337–43.
48. Mir O, Berveiller P, Ropert S, Goffinet F, Pons G, Treluyer JM, et al. Emerging therapeutic options for breast cancer chemotherapy during pregnancy. Ann Oncol. 2008;19:607–13.
49. Han SN, Amant F. Trastuzumab, lapatinib and bevacizumab during pregnancy. Breast Cancer Manag. 2014;2:5–7.
50. Petrou P, Georgalas I, Giavaras G, Anastasiou E, Ntana Z, Petrou C. Early loss of pregnancy after intravitreal bevacizumab injection. Acta Ophthalmol. 2010;88:e136.
51. Stensheim H, Moller B, van Dijk T, Fossa SD. Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study. J Clin Oncol. 2009;27:45–51.
52. Blake EA, Carter CM, Kashani BN, Kodama M, Mabuchi S, Yoshino K, et al. Feto-maternal outcomes of pregnancy complicated by ovarian sex-cord stromal tumor: a systematic review of literature. Eur J Obstet Gynecol Reprod Biol. 2014;175C:1–7.
53. Chervenak FA, McCullough LB, Knapp RC, Caputo TA, Barber HR. A clinically comprehensive ethical framework for offering and recommending cancer treatment before and during pregnancy. Cancer. 2004;100:215–22.